The evolution of epilepsy treatment: Lessons from a century of progress

Notice: Blog posts are not subject to review by MedLink Neurology’s Editorial Board. MedLink acknowledges using artificial intelligence to assist in the creation of blog posts.

Over the past century, epilepsy management has undergone a transformative journey. From rudimentary treatments rooted in trial and error to precise, individualized care, the evolution of epilepsy management reflects the medical field’s relentless pursuit of better patient outcomes. Central to this progress is the role of experience—clinical, technological, and scientific—in refining our understanding and treatment of epilepsy. This blog post explores how lessons from the past have shaped modern epilepsy care, with specific examples illustrating key milestones.

The rise of monotherapy: a paradigm shift

A significant turning point in epilepsy management was the recognition that monotherapy—using a single antiepileptic drug (AED)—should be the gold standard. In the early 20th century, polypharmacy was the norm. Clinicians combined multiple drugs, often with overlapping mechanisms, in an attempt to control seizures. Although this approach occasionally succeeded, it frequently led to intolerable side effects, drug interactions, and poor adherence.

The discovery of phenytoin in 1938 by Tracy Putnam and H. Houston Merritt marked the beginning of a shift. Phenytoin’s efficacy in controlling seizures without the sedative effects of earlier drugs like bromides or barbiturates demonstrated that a single drug could be both effective and tolerable. Subsequent decades saw the development of more targeted AEDs, such as carbamazepine and valproate, which further validated the concept of monotherapy. Today, clinicians prioritize monotherapy for most patients, optimizing the dose of one drug before considering additional therapies.

Targeted treatments for specific seizure types

Experience has shown that not all seizures are created equal. Early epilepsy treatments took a one-size-fits-all approach, often leading to suboptimal results. Advances in diagnostic tools, particularly electroencephalography (EEG) and high-resolution imaging, enabled the differentiation of seizure types and epilepsy syndromes. This, in turn, informed the development of targeted treatments.

For example, ethosuximide, introduced in the 1960s, became the first-line treatment for absence seizures, a type of generalized seizure common in children. Its specificity and effectiveness demonstrated the value of tailoring therapy to the underlying seizure type. Similarly, the identification of Lennox-Gastaut syndrome and Dravet syndrome led to the approval of drugs like cannabidiol and fenfluramine, designed to address the unique challenges of these conditions.

The role of therapeutic drug monitoring

In the mid-20th century, clinicians began monitoring blood levels of AEDs to fine-tune dosages and minimize side effects. Drugs like phenytoin, with narrow therapeutic windows, particularly benefited from this practice. By ensuring that blood levels remained within the optimal range, clinicians could avoid toxicity while maximizing efficacy. Although newer AEDs like levetiracetam have wider therapeutic indices and require less monitoring, therapeutic drug monitoring remains essential for certain populations, such as pregnant women, children, and patients on multiple medications.

Technological innovations in seizure detection

One of the most profound advancements in epilepsy management has been the integration of technology into seizure monitoring. In the past, seizure control was assessed primarily through patient self-reports or caregiver observations, which were often incomplete or inaccurate. The advent of video-EEG monitoring revolutionized diagnostics, allowing clinicians to capture and analyze seizures in real time.

Wearable devices have further improved seizure monitoring. For instance, the Embrace watch uses electrodermal activity and motion sensors to detect convulsive seizures and alert caregivers. These technologies provide critical data for tailoring treatment plans and improving patient safety, particularly for nocturnal seizures that might otherwise go unnoticed.

Comprehensive, holistic care

Past experience has underscored the importance of addressing not just seizures but the broader impact of epilepsy on patients’ lives. Early epilepsy care focused narrowly on seizure control, often neglecting issues like cognitive side effects, mental health, and social stigma. Today, a holistic approach integrates these factors into treatment plans.

For example, the ketogenic diet, once dismissed as a relic of the 1920s, experienced a resurgence in the 1990s as a nonpharmacological option for drug-resistant epilepsy. Similarly, advancements in epilepsy surgery and neurostimulation therapies, such as vagus nerve stimulation and responsive neurostimulation, offer alternative solutions for patients who do not respond to medication.

The road ahead

The evolution of epilepsy management is a testament to the power of learning from experience. Each breakthrough—whether a new drug, diagnostic tool, or therapy—builds on the lessons of the past. Although challenges remain, particularly in addressing drug-resistant epilepsy and improving access to care, the trajectory of progress offers hope.

As we move forward, the integration of artificial intelligence, personalized medicine, and advanced monitoring tools promises to further refine epilepsy care. By continuing to learn from past successes and challenges, we can ensure a future where every patient receives the best possible treatment.

Related MedLink Neurology Podcast content:

• BrainWaves #146 Tangled up in squiggles: EEG 101 and the ictal inter-ictal continuum
• The Neurotransmitters: IM Board Prep #4: Seizures and Epilepsy
  
• Neuro Podcases: An approach to epilepsy
  
• BrainWaves #178 First seizure of life
  

Are you interested in contributing a post or becoming a guest blogger for MedLink? Contact us at editorial@medlink.com.